Mercaptopurine Bioavailability
To the Editor: On the basis of pharmacokinetic data, Zimm et al., 1 have questioned whether an optimal amount of mercaptopurine is currently being given in maintenance chemotherapy regimens for acute lymphoblastic leukemia (April 28, 1983, issue). They suggest that giving mercaptopurine intravenousl...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1984-04, Vol.310 (14), p.929-929 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 929 |
|---|---|
| container_issue | 14 |
| container_start_page | 929 |
| container_title | The New England journal of medicine |
| container_volume | 310 |
| creator | Rundles, R. Wayne Elion, Gertrude B |
| description | To the Editor:
On the basis of pharmacokinetic data, Zimm et al.,
1
have questioned whether an optimal amount of mercaptopurine is currently being given in maintenance chemotherapy regimens for acute lymphoblastic leukemia (April 28, 1983, issue). They suggest that giving mercaptopurine intravenously, rather than orally, and monitoring the dose by determining blood levels might increase the effectiveness of this agent and reduce the relapse rate in acute lymphoblastic leukemia, which is still about 50 per cent.
2
,
3
The biochemical pharmacology of mercaptopurine may be more important than the pharmacokinetic data. Mercaptopurine is a prodrug that becomes active only after conversion to . . . |
| doi_str_mv | 10.1056/NEJM198404053101420 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80986147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80986147</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-380e5346144779749fc3ff2aa449ea6c3f90d7955dd664404ee15eb87a869db93</originalsourceid><addsrcrecordid>eNp9kM1LAzEQxYMotVb_AlE8eZHVSTP5OtpSv2j1oueQ3c1Cym53TXaF_vdGWjyJcxmG996P4RFyTuGWAhd3r4uXFdUKAYEzChSncEDGlDOWIYI4JGOAqcpQanZMTmJcQxqKekRGgivGQY3J5cqFwnZ92w3Bb9zVzLf2y_ra5r72_faUHFW2ju5svyfk42HxPn_Klm-Pz_P7ZVYwJvqMKXCcoaCIUmqJuipYVU2tRdTOinRoKKXmvCyFSL-hc5S7XEmrhC5zzSbkesftQvs5uNibxsfC1bXduHaIRoFWiS6Tke2MRWhjDK4yXfCNDVtDwfy0Yv5oJaUu9vghb1z5m9nXkPSbnd400WzcuvmX9g1dcWcv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80986147</pqid></control><display><type>article</type><title>Mercaptopurine Bioavailability</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Rundles, R. Wayne ; Elion, Gertrude B</creator><creatorcontrib>Rundles, R. Wayne ; Elion, Gertrude B</creatorcontrib><description>To the Editor:
On the basis of pharmacokinetic data, Zimm et al.,
1
have questioned whether an optimal amount of mercaptopurine is currently being given in maintenance chemotherapy regimens for acute lymphoblastic leukemia (April 28, 1983, issue). They suggest that giving mercaptopurine intravenously, rather than orally, and monitoring the dose by determining blood levels might increase the effectiveness of this agent and reduce the relapse rate in acute lymphoblastic leukemia, which is still about 50 per cent.
2
,
3
The biochemical pharmacology of mercaptopurine may be more important than the pharmacokinetic data. Mercaptopurine is a prodrug that becomes active only after conversion to . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM198404053101420</identifier><identifier>PMID: 6583508</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Biological Availability ; Child ; Humans ; Leukemia, Lymphoid - drug therapy ; Mercaptopurine - metabolism</subject><ispartof>The New England journal of medicine, 1984-04, Vol.310 (14), p.929-929</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-380e5346144779749fc3ff2aa449ea6c3f90d7955dd664404ee15eb87a869db93</citedby><cites>FETCH-LOGICAL-c336t-380e5346144779749fc3ff2aa449ea6c3f90d7955dd664404ee15eb87a869db93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,64387</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6583508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rundles, R. Wayne</creatorcontrib><creatorcontrib>Elion, Gertrude B</creatorcontrib><title>Mercaptopurine Bioavailability</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
On the basis of pharmacokinetic data, Zimm et al.,
1
have questioned whether an optimal amount of mercaptopurine is currently being given in maintenance chemotherapy regimens for acute lymphoblastic leukemia (April 28, 1983, issue). They suggest that giving mercaptopurine intravenously, rather than orally, and monitoring the dose by determining blood levels might increase the effectiveness of this agent and reduce the relapse rate in acute lymphoblastic leukemia, which is still about 50 per cent.
2
,
3
The biochemical pharmacology of mercaptopurine may be more important than the pharmacokinetic data. Mercaptopurine is a prodrug that becomes active only after conversion to . . .</description><subject>Biological Availability</subject><subject>Child</subject><subject>Humans</subject><subject>Leukemia, Lymphoid - drug therapy</subject><subject>Mercaptopurine - metabolism</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LAzEQxYMotVb_AlE8eZHVSTP5OtpSv2j1oueQ3c1Cym53TXaF_vdGWjyJcxmG996P4RFyTuGWAhd3r4uXFdUKAYEzChSncEDGlDOWIYI4JGOAqcpQanZMTmJcQxqKekRGgivGQY3J5cqFwnZ92w3Bb9zVzLf2y_ra5r72_faUHFW2ju5svyfk42HxPn_Klm-Pz_P7ZVYwJvqMKXCcoaCIUmqJuipYVU2tRdTOinRoKKXmvCyFSL-hc5S7XEmrhC5zzSbkesftQvs5uNibxsfC1bXduHaIRoFWiS6Tke2MRWhjDK4yXfCNDVtDwfy0Yv5oJaUu9vghb1z5m9nXkPSbnd400WzcuvmX9g1dcWcv</recordid><startdate>19840405</startdate><enddate>19840405</enddate><creator>Rundles, R. Wayne</creator><creator>Elion, Gertrude B</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19840405</creationdate><title>Mercaptopurine Bioavailability</title><author>Rundles, R. Wayne ; Elion, Gertrude B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-380e5346144779749fc3ff2aa449ea6c3f90d7955dd664404ee15eb87a869db93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Biological Availability</topic><topic>Child</topic><topic>Humans</topic><topic>Leukemia, Lymphoid - drug therapy</topic><topic>Mercaptopurine - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rundles, R. Wayne</creatorcontrib><creatorcontrib>Elion, Gertrude B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rundles, R. Wayne</au><au>Elion, Gertrude B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mercaptopurine Bioavailability</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1984-04-05</date><risdate>1984</risdate><volume>310</volume><issue>14</issue><spage>929</spage><epage>929</epage><pages>929-929</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
On the basis of pharmacokinetic data, Zimm et al.,
1
have questioned whether an optimal amount of mercaptopurine is currently being given in maintenance chemotherapy regimens for acute lymphoblastic leukemia (April 28, 1983, issue). They suggest that giving mercaptopurine intravenously, rather than orally, and monitoring the dose by determining blood levels might increase the effectiveness of this agent and reduce the relapse rate in acute lymphoblastic leukemia, which is still about 50 per cent.
2
,
3
The biochemical pharmacology of mercaptopurine may be more important than the pharmacokinetic data. Mercaptopurine is a prodrug that becomes active only after conversion to . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>6583508</pmid><doi>10.1056/NEJM198404053101420</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1984-04, Vol.310 (14), p.929-929 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80986147 |
| source | MEDLINE; ProQuest Central UK/Ireland |
| subjects | Biological Availability Child Humans Leukemia, Lymphoid - drug therapy Mercaptopurine - metabolism |
| title | Mercaptopurine Bioavailability |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mercaptopurine%20Bioavailability&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Rundles,%20R.%20Wayne&rft.date=1984-04-05&rft.volume=310&rft.issue=14&rft.spage=929&rft.epage=929&rft.pages=929-929&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM198404053101420&rft_dat=%3Cproquest_cross%3E80986147%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80986147&rft_id=info:pmid/6583508&rfr_iscdi=true |